KIRKLAND, WASHINGTON - April 5, 1999 - Radiant Research, a company of premier clinical research sites, today announced it has raised $14.2 million in its second round of financing. The lead investor in this round was ABS Capital Partners, a private equity fund with approximately $850 million of capital under management. ABS Capital Partners was joined by all of the original investors including Mayfield Fund, Oak Investment Partners and Salix Ventures.

"We are extremely pleased to be an investor in the clinical trials marketplace, and more specifically with Radiant Research," commented John Stobo, General Partner of ABS Capital Partners. "As more and more pharmaceutical products come down the R&D pipeline, the bottleneck will be around finding patients to test the drugs. Radiant's rapid growth and their extensive research experience put them in a great position to help pharmaceutical and biotechnology companies solve this issue. We are very impressed with the Leadership Team and the significant progress they have made over the past year. We are particularly impressed with the premium brand they have built through the quality of their acquisitions."

"We are very happy to have ABS Capital Partners as part of our investor group," said Michael Lester, president and CEO of Radiant Research. "Their commitment to Radiant and to the clinical trials marketplace will support Radiant's growth and allow us to continue to build our organization. The relationship with ABS Capital Partners is also important for us, given their extensive experience in the health care industry and the capital markets."

The Company, headquartered in Kirkland, Washington, now has 11 research sites in Arizona, California, Hawaii, Florida, Kansas, New Jersey, and Pennsylvania. The Company has plans to double its investigative team in the next year.

                                                             ###

About Radiant Research
Based near Seattle, Washington, Radiant Research (radiantresearch.com) is a comprehensive clinical research and development company serving the biopharmaceutical and medical device industry. Radiant is comprised of more than 30 wholly-owned premier clinical research centers nationwide, employing over 500 clinical research professionals exclusively focused on providing professional, high quality study conduct and drug development services. In the past four years, Radiant has conducted more than 8,000 clinical trials across 18 therapeutic specialties.

Contact:
Michael K. Lester Chief Executive Officer RADIANT RESEARCH (425) 468-6200	Pamela M. Spaniac Chief Financial Officer RADIANT RESEARCH (425) 468-6200